Table 1. Comparison of clinical factors between patients with different statuses of 2-year survival.
| 2-year survival | P value | ||
|---|---|---|---|
| < 2 year (n = 30) | > 2 year (n = 21) | ||
| age (yr) | 62.07 | 43.86 | 0.001 |
| Sex | |||
| Female | 14 | 14 | 0.158 |
| Male | 16 | 7 | |
| Pathologic Diagnosis | |||
| AST | 0 | 7 | <0.001* |
| AA | 5 | 9 | |
| GBM | 25 | 5 | |
| Tumor volume (median) (cm3) | 29.91 | 9.7 | 0.016 |
| Surgical Intervention | |||
| Biopsy | 14 | 8 | 0.210 |
| Subtotal or partial resection | 7 | 2 | |
| Total resection | 9 | 11 | |
| Initial Treatment | |||
| AA | |||
| CCRT | 3 | 7 | 0.580* |
| Chemotherapy or radiation alone | 2 | 2 | |
| GBM | |||
| CCRT | 20 | 5 | 0.556* |
| Chemotherapy or radiation alone | 5 | 0 | |
| AA+GBM | |||
| CCRT | 23 | 12 | 0.695* |
| Chemotherapy or radiation alone | 7 | 2 | |
| Follow-up Treatment | |||
| Adjuvant Temozolomide | |||
| yes | 20 | 13 | 0.726 |
| no | 10 | 8 | |
| Bevacizumab | |||
| yes | 14 | 6 | 0.193 |
| no | 16 | 15 | |
| other chemotherapy agents | |||
| yes | 12 | 4 | 0.113 |
| no | 18 | 17 | |
| Radiation | |||
| yes | 4 | 3 | 1.000* |
| no | 26 | 18 | |
Note: Values are number of patients unless otherwise indicated. P values were calculated by using Chi-square test unless specified.
* Fisher-exact test was used for comparison. AST, astrocytoma; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; CCRT, concurrent chemoradiation therapy with temozolomide.